ClinVar Miner

Submissions for variant NM_000169.3(GLA):c.427G>C (p.Ala143Pro) (rs104894845)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000157890 SCV000110120 pathogenic not provided 2013-11-13 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000011516 SCV000205984 likely pathogenic Fabry disease 2014-01-17 criteria provided, single submitter clinical testing The Arg143Pro variant in GLA as been reported in 6 males with Fabry disease, 5 o f whom were of Nova Scotian ancestry (Eng 1994, Branton 2002, Glass 2004). For 2 of them, absence of alpha-galatosidase enzyme activity was reported (Branton 2002). This variant was not identified in large population studies. Computation al analyses (biochemical amino acid properties, conservation, AlignGVGD, PolyPhe n2, and SIFT) do not provide strong support for or against an impact to the prot ein. Finally, another variant at this position (Arg143Thr) has been reported in multiple individuals with Fabry disease, segregated with disease (Spada 2006, Te rryn 2008), and is considered disease-causing, further supporting that a change at this position is not tolerated. In summary, the presence in multiple affected individuals, absence from large populations, and presence of another variant at the same position all support that this variant is likely to be pathogenic, tho ugh additional studies are required to fully establish its clinical significance .
GeneDx RCV000157890 SCV000207821 pathogenic not provided 2016-04-23 criteria provided, single submitter clinical testing The A143P pathogenic variant has been reported previously in a patient with the classic phenotype of Fabry disease (Eng et al., 1994).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000011516 SCV001361589 pathogenic Fabry disease 2021-01-12 criteria provided, single submitter clinical testing Variant summary: GLA c.427G>C (p.Ala143Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183467 control chromosomes (gnomAD). c.427G>C has been reported in the literature in at least an individual affected with Classic Fabry Disease (example: Eng_1994). These data indicate that the variant is likely to be associated with disease. Enzymatic activity from patient derived samples as well as in vitro studies reveal that the variant resulted in reduced or no enzymatic activity (Altarescu_2001, Lukas_2013). One other ClinVar submitter (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
OMIM RCV000011516 SCV000031748 pathogenic Fabry disease 2002-03-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.